Compare INVZ & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVZ | FHTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.5M | 246.6M |
| IPO Year | N/A | 2020 |
| Metric | INVZ | FHTX |
|---|---|---|
| Price | $1.30 | $4.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $3.10 | ★ $11.86 |
| AVG Volume (30 Days) | ★ 5.0M | 190.5K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,442,000.00 | $24,518,000.00 |
| Revenue This Year | $146.75 | $47.50 |
| Revenue Next Year | $53.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.09 | N/A |
| 52 Week Low | $0.48 | $2.95 |
| 52 Week High | $3.14 | $6.79 |
| Indicator | INVZ | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 47.08 |
| Support Level | $1.24 | $4.33 |
| Resistance Level | $1.38 | $4.82 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 59.62 | 10.15 |
Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.